Codetta Bio™ Expands Global Commercial Leadership to Accelerate Worldwide Adoption of the Concerto™ SystemDURHAM, N.C., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Codetta Bio™, a leading innovator in multi-omic solutions that integrate ultrasensitive protein quantitation with simultaneous analysis of nucleic acids (RNA and DNA), today announced a significant expansion of its global commercial organization. This strategic move strengthens the company’s ability to meet growing demand for its Concerto™ system as Codetta transitions from its Technology Access Program (TAP) to full commercial launch.
Codetta Bio Launches Concerto™ System at AACR 2025 and Invites Attendees to Be a Part of “The Opening Concerto”Experience the harmony of multi-omics with Codetta Bio’s groundbreaking Concerto™ System—and be among the first to play a leading role in its debut
Codetta Bio to Launch Concerto™ System at AACR 2025 with Exhibitor Spotlight PresentationDURHAM, N.C., April 23, 2025 (GLOBE NEWSWIRE) -- Codetta Bio, a leader in multi-omics innovation, today announced its presence at the American Association for Cancer Research (AACR) Annual Meeting 2025, where the company will officially launch the Concerto™ System, the first platform to enable simultaneous, quantitative measurement of proteins, DNA, and RNA from a single sample.
Codetta Bio Welcomes Paul McEwan and Mitch Levine as Independent Board MembersMORRISVILLE, N.C., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Codetta Bio, a leader in integrated multi-omics solutions, is proud to announce the addition of two distinguished professionals, Paul McEwan and Mitch Levine, as independent members to the Board of Directors. These seasoned experts bring decades of experience in life sciences, investment strategy, and corporate growth, further strengthening Codetta Bio’s leadership as it continues to innovate in the multi-omics space.
